Integrated Exposure–Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis

Emily Briggs, Mohamed A. Kamal*, Matthew P. Kosloski, Ian Linsmeier, Natalie Jusko, Nancy Dolphin, Jason Chittenden, Eric L. Simpson, Amy S. Paller, Elaine C. Siegfried, Brad Shumel, Noah A. Levit, Ashish Bansal, John D. Davis, Sunny Chapel, David E. Smith, Nidal Huniti

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: While the majority of patients with atopic dermatitis (AD) achieve disease control with dupilumab treatment, there is variability in which patients achieve clear disease. The predictors of these responses are currently unclear. Integrated models were developed to evaluate the exposure–response (E-R) relationship of dupilumab in children, adolescents, and adults with AD. Methods: Data from six Phase II and III clinical studies were pooled (2,366 adults [> 18 years], 243 adolescents [≥ 12 to < 18 years] and 359 children [≥ 6 to < 12 years]) for model development. Efficacy was assessed using the Eczema Area and Severity Index (EASI) and Investigator’s Global Assessment (IGA). Indirect response models were applied to link measures of efficacy and functional serum dupilumab concentrations. The covariates on individual placebo-corrected response were assessed. Clinical trial scenarios were simulated to compare E-R relationships across age groups. Safety was not explored. Results: After correcting for differences in placebo response and dupilumab exposure: 1) older age, higher body weight, lower baseline thymus and activation-regulated chemokine, and Asian race were associated with slightly lower EASI response, and no clear covariates were identified on IGA response; 2) clinical trial simulations generally showed slightly higher response at a given dupilumab concentration in children compared to adults and adolescents with severe and moderate AD. Conclusions: The collectively tested covariates explain some of the variability in dupilumab response in patients with AD. Patients in all age groups showed adequate response to dupilumab; however, children showed slightly higher drug effects compared to adults and adolescents at equivalent concentrations.

Original languageEnglish (US)
Pages (from-to)2653-2666
Number of pages14
JournalPharmaceutical Research
Volume40
Issue number11
DOIs
StatePublished - Nov 2023

Keywords

  • atopic dermatitis
  • dupilumab
  • exposure–response
  • pediatrics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Molecular Medicine
  • Biotechnology
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Integrated Exposure–Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis'. Together they form a unique fingerprint.

Cite this